drugset / Trial / NCT04330326
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
Phase 2
Completed
32 enrolled
ScandiBio Therapeutics AB
Göteborg University · collabHelsinki University Central Hospital · collabKTH Royal Institute of Technology · collabKoc University Hospital · collabKoç University · collabMonitorCRO · collabSahlgrenska University Hospital · collabUniversity of Helsinki · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This short-term, randomized, placebo-controlled, investigator-initiated trial aims to establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine. Concomitant use of pivotal metabolic cofactors via simultaneous dietary supplementation will stimulate three different pathways to enhance hepatic β-oxidation and this study's hypothesis is that this will result in decreased amount of fat in the liver.
Timeline
- Start
- 2019-07-20
- Primary completion
- 2020-07-29
- Completion
- 2022-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-carnitine | Other / unclassified | — | Oral |
| Subject | N-acetylcysteine | Small molecule | — | Oral |
| Subject | Nicotinamide riboside | Small molecule | — | Oral |
| Subject | Serine | Unknown | — | Oral |